MEP53308A - Novel peptides that bind to the erythropoietin receptor - Google Patents
Novel peptides that bind to the erythropoietin receptorInfo
- Publication number
- MEP53308A MEP53308A MEP-533/08A MEP53308A MEP53308A ME P53308 A MEP53308 A ME P53308A ME P53308 A MEP53308 A ME P53308A ME P53308 A MEP53308 A ME P53308A
- Authority
- ME
- Montenegro
- Prior art keywords
- erythropoietin receptor
- bind
- novel peptides
- peptide compounds
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47024403P | 2003-05-12 | 2003-05-12 | |
US46999303P | 2003-05-12 | 2003-05-12 | |
PCT/US2004/014889 WO2004101606A2 (en) | 2003-05-12 | 2004-05-12 | Novel peptides that bind to the erythropoietin receptor |
YUP-2005/0838A RS51130B (sr) | 2003-05-12 | 2004-05-12 | Novi peptidi koji se vezuju za eritropoietinski receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
ME00356B ME00356B (me) | 2011-05-10 |
MEP53308A true MEP53308A (en) | 2011-05-10 |
Family
ID=33457168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-533/08A MEP53308A (en) | 2003-05-12 | 2004-05-12 | Novel peptides that bind to the erythropoietin receptor |
Country Status (33)
Country | Link |
---|---|
US (4) | US7084245B2 (pt) |
EP (1) | EP1629007B1 (pt) |
JP (2) | JP4266028B2 (pt) |
KR (1) | KR101163683B1 (pt) |
CN (1) | CN100441595C (pt) |
AP (1) | AP2042A (pt) |
AT (1) | ATE428727T1 (pt) |
AU (1) | AU2004238870B8 (pt) |
BR (1) | BRPI0411155A (pt) |
CA (1) | CA2525568C (pt) |
CR (1) | CR8131A (pt) |
CY (1) | CY1109028T1 (pt) |
DE (1) | DE602004020610D1 (pt) |
DK (1) | DK1629007T3 (pt) |
EA (1) | EA010095B1 (pt) |
ES (1) | ES2323465T3 (pt) |
HK (1) | HK1088616A1 (pt) |
HR (1) | HRP20090251T1 (pt) |
IL (1) | IL171782A (pt) |
IS (1) | IS2683B (pt) |
ME (1) | MEP53308A (pt) |
MX (1) | MXPA05012316A (pt) |
NO (1) | NO338435B1 (pt) |
NZ (1) | NZ543905A (pt) |
OA (1) | OA13164A (pt) |
PL (1) | PL1629007T3 (pt) |
PT (1) | PT1629007E (pt) |
RS (1) | RS51130B (pt) |
SG (1) | SG160224A1 (pt) |
SI (1) | SI1629007T1 (pt) |
UA (1) | UA88146C2 (pt) |
WO (1) | WO2004101606A2 (pt) |
ZA (1) | ZA200510010B (pt) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7259146B2 (en) | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
EA010099B1 (ru) * | 2003-05-12 | 2008-06-30 | Афимакс, Инк. | Пептиды, которые связываются с рецептором к эритропоэтину, и способы их применения |
MXPA05012316A (es) | 2003-05-12 | 2006-04-18 | Affymax Inc | Peptidos novedosos que se unen al receptor de la eritropoyetina. |
BRPI0411160A (pt) * | 2003-05-12 | 2006-07-11 | Affymax Inc | novos compostos modificados com poli(glicol etilênico) e usos dos mesmos |
KR101160611B1 (ko) * | 2003-05-12 | 2012-06-28 | 아피맥스, 인크. | 폴리(에틸렌 글리콜)로 변형된 펩티드 기재 화합물용 신규 스페이서 부분 |
EA200901463A1 (ru) | 2004-02-20 | 2010-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Ингибиторы вирусной полимеразы |
DE102004031258A1 (de) * | 2004-06-29 | 2006-02-09 | Jennissen, Herbert P., Prof. Dr. | Proteinhybride mit polyhydroxyaromatischen Aminosäure-Epitopen |
US7589063B2 (en) | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
EA200700990A1 (ru) * | 2004-11-11 | 2008-04-28 | Афимакс, Инк. | Новые пептиды, которые связывают рецептор эритропоэтина |
US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
WO2009025957A1 (en) * | 2007-08-22 | 2009-02-26 | Takeda Pharmaceuticals Company Limited | Erythropoietin receptor peptide formulations and uses |
US7919461B2 (en) * | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
GB0523954D0 (en) * | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
WO2007070372A2 (en) * | 2005-12-09 | 2007-06-21 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
EP2035041B1 (en) | 2006-06-30 | 2020-01-08 | Syntab Therapeutics GmbH | Conjugates for innate immunotherapy of cancer |
US20080193942A1 (en) | 2006-11-08 | 2008-08-14 | Don Wojchowski | System and method for identifying erythropoietin-responsive genes |
WO2008065372A2 (en) | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
EP2118127A4 (en) | 2007-01-31 | 2010-12-01 | Affymax Inc | NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES |
JP2010517529A (ja) * | 2007-02-02 | 2010-05-27 | アムジエン・インコーポレーテツド | ヘプシジン及びヘプシジン抗体 |
US20090131317A1 (en) * | 2007-06-22 | 2009-05-21 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
EP2018835B1 (de) | 2007-07-09 | 2014-03-05 | Augustinus Bader | Wirkstoff abgebendes Pflaster |
US8383114B2 (en) * | 2007-09-27 | 2013-02-26 | Amgen Inc. | Pharmaceutical formulations |
ES2962777T3 (es) | 2007-11-15 | 2024-03-21 | Amgen Inc | Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral |
CN101456911A (zh) * | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
JP2011508777A (ja) * | 2008-01-07 | 2011-03-17 | セントコア・オーソ・バイオテツク・インコーポレーテツド | エリスロポエチン低応答性貧血を治療する方法 |
KR20190085187A (ko) | 2008-01-22 | 2019-07-17 | 아라임 파마슈티칼즈, 인크. | 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
MX2010008096A (es) | 2008-01-25 | 2010-09-22 | Amgen Inc | Anticuerpos de ferroportina y metodos de uso. |
JP2009191056A (ja) * | 2008-02-15 | 2009-08-27 | Affymax Inc | 合成ペプチドをベースとするepoレセプターアゴニストを用いた抗エリスロポエチン抗体に媒介された障害の治療 |
JP2011519279A (ja) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
WO2010056981A2 (en) | 2008-11-13 | 2010-05-20 | Massachusetts General Hospital | Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
WO2011012306A2 (en) | 2009-07-30 | 2011-02-03 | Aplagen Gmbh | Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis |
WO2011050333A1 (en) | 2009-10-23 | 2011-04-28 | Amgen Inc. | Vial adapter and system |
MX2012014180A (es) | 2010-06-07 | 2013-05-06 | Amgen Inc | Dispositivo de administracion de farmacos. |
ES2632164T3 (es) | 2010-07-06 | 2017-09-11 | Augustinus Bader | Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea |
EP2471945A1 (de) * | 2010-12-30 | 2012-07-04 | Siemens Healthcare Diagnostics Products GmbH | Verfahren zur Bestimmung von Inhibitoren der Gerinnung |
EP2691065B1 (en) | 2011-03-31 | 2017-03-01 | Amgen Inc. | Vial adapter and system |
CA3021845C (en) | 2011-04-20 | 2022-03-29 | Amgen Inc. | Autoinjector apparatus |
EP2709648A4 (en) | 2011-05-19 | 2015-04-08 | Geysen Hendrik M | COMPOUNDS FOR BINDING TO THE ERYTHROPOIETIN RECEPTOR |
IL308846A (en) | 2011-10-14 | 2024-01-01 | Amgen Inc | Syringe and assembly method |
MX2015006343A (es) | 2012-11-21 | 2015-10-05 | Amgen Inc | Dispositivo de administracion de farmacos. |
DK2968503T3 (en) | 2013-03-15 | 2018-12-03 | Intrinsic Lifesciences Llc | ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF |
CA2904661C (en) | 2013-03-15 | 2022-03-15 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
TWI580451B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法 |
CN113559363B (zh) | 2013-03-22 | 2023-10-31 | 美国安进公司 | 注射器及装配方法 |
CN104231067B (zh) * | 2013-06-07 | 2017-08-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 促红细胞生成素模拟肽化学二聚体及其用途 |
WO2015061386A1 (en) | 2013-10-24 | 2015-04-30 | Amgen Inc. | Injector and method of assembly |
CA2926110C (en) | 2013-10-24 | 2023-05-23 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
WO2015171777A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
AU2015271676A1 (en) | 2014-06-03 | 2016-11-10 | Amgen Inc. | Devices and methods for assisting a user of a drug delivery device |
WO2016049036A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
WO2016061220A2 (en) | 2014-10-14 | 2016-04-21 | Amgen Inc. | Drug injection device with visual and audio indicators |
WO2016100055A1 (en) | 2014-12-19 | 2016-06-23 | Amgen Inc. | Drug delivery device with live button or user interface field |
WO2016100781A1 (en) | 2014-12-19 | 2016-06-23 | Amgen Inc. | Drug delivery device with proximity sensor |
CA3069716C (en) | 2015-02-17 | 2021-11-09 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
ES2905870T3 (es) | 2015-02-27 | 2022-04-12 | Amgen Inc | Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
CN106554394B (zh) * | 2015-09-30 | 2019-08-16 | 天津药物研究院有限公司 | 一种促红细胞生成素模拟肽及其制备方法和应用 |
US10138273B2 (en) * | 2015-10-07 | 2018-11-27 | The Curators Of The University Of Missouri | Peptide ligands for hepatic stellate cells |
EP3386573B1 (en) | 2015-12-09 | 2019-10-02 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
EP3721922B1 (en) | 2016-03-15 | 2022-05-04 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
GB2550114A (en) * | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
MX2018013616A (es) | 2016-05-13 | 2019-02-21 | Amgen Inc | Montaje de cubierta protectora de vial. |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
GB201609083D0 (en) | 2016-05-24 | 2016-07-06 | Syntab Therapeutics Gmbh | Synthetic compound |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
EP3478342A1 (en) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
EP3582825A1 (en) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
EP3592403A1 (en) | 2017-03-06 | 2020-01-15 | Amgen Inc. | Drug delivery device with activation prevention feature |
MX2019010543A (es) | 2017-03-07 | 2019-10-21 | Amgen Inc | Insercion de agujas por sobrepresion. |
IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
EP3570871B1 (en) | 2017-03-20 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
AU2018245995B2 (en) | 2017-03-28 | 2024-03-07 | Amgen Inc. | Plunger rod and syringe assembly system and method |
US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
MX2019014615A (es) | 2017-06-08 | 2020-02-07 | Amgen Inc | Dispositivo de administracion de farmacos accionado por par de torsion. |
MX2019015472A (es) | 2017-06-22 | 2020-02-19 | Amgen Inc | Reduccion del impacto/choque de la activacion del mecanismo. |
EP3641861A1 (en) | 2017-06-23 | 2020-04-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
EP3651832B1 (en) | 2017-07-14 | 2023-12-13 | Amgen Inc. | Needle insertion-retraction system having dual torsion spring system |
JP2020527376A (ja) | 2017-07-21 | 2020-09-10 | アムジエン・インコーポレーテツド | 薬物容器のためのガス透過性シーリング部材及び組立方法 |
JP2020528296A (ja) | 2017-07-25 | 2020-09-24 | アムジエン・インコーポレーテツド | ギヤモジュールを有する薬物送達デバイス及び関連する組立方法 |
WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF |
US20200164155A1 (en) | 2017-08-09 | 2020-05-28 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
MA49897A (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc | Injecteur sur-corps avec patch adhésif stérile |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
US11759565B2 (en) | 2017-10-04 | 2023-09-19 | Amgen Inc. | Flow adapter for drug delivery device |
EP3691716B1 (en) | 2017-10-06 | 2023-11-29 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
WO2019074579A1 (en) | 2017-10-09 | 2019-04-18 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF |
WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
EP3706830A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Drug delivery device with placement and flow sensing |
CN116832271A (zh) | 2017-11-10 | 2023-10-03 | 安进公司 | 用于药物递送装置的柱塞 |
MA50904A (fr) | 2017-11-16 | 2020-09-23 | Amgen Inc | Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament |
AU2018368338A1 (en) | 2017-11-16 | 2020-04-09 | Amgen Inc. | Autoinjector with stall and end point detection |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
MA53375A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
CA3106452A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
IL281469B1 (en) | 2018-09-28 | 2024-04-01 | Amgen Inc | Assembling a memory alloy ejector activation assembly for a drug delivery device |
CA3110529A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
TWI824026B (zh) | 2018-10-05 | 2023-12-01 | 美商安進公司 | 具有劑量指示器之藥物遞送裝置 |
MX2021004219A (es) | 2018-10-15 | 2021-05-27 | Amgen Inc | Dispositivo de administracion de farmacos con mecanismo de amortiguacion. |
SG11202101824VA (en) | 2018-10-15 | 2021-03-30 | Amgen Inc | Platform assembly process for drug delivery device |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
US20220031939A1 (en) | 2018-11-01 | 2022-02-03 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
EP3958934A1 (en) | 2019-04-24 | 2022-03-02 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
AU2020337250A1 (en) | 2019-08-23 | 2022-03-03 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
CN117320964A (zh) | 2021-05-21 | 2023-12-29 | 美国安进公司 | 优化药物容器的灌装方案的方法 |
WO2023209074A1 (en) | 2022-04-28 | 2023-11-02 | Institut National de la Santé et de la Recherche Médicale | Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing |
WO2024094457A1 (en) | 2022-11-02 | 2024-05-10 | F. Hoffmann-La Roche Ag | Method for producing glycoprotein compositions |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4677195A (en) * | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
WO1990008822A1 (en) * | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
ATE136315T1 (de) | 1989-05-27 | 1996-04-15 | Sumitomo Pharma | Verfahren für die herstellung von polyethylenglykolderivate und modifizierte proteine. |
US5292654A (en) * | 1990-12-13 | 1994-03-08 | Whitehead Institute For Biomedical Research | Mutant EPO receptor and uses therefor |
JP3693671B2 (ja) | 1991-03-15 | 2005-09-07 | アムゲン インコーポレーテッド | ポリペプチドのpeg化 |
AU1676992A (en) | 1991-03-18 | 1992-10-21 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
US6153407A (en) * | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5830851A (en) * | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
US5580853A (en) * | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
US5919758A (en) * | 1994-03-22 | 1999-07-06 | Beth Israel Deaconess Medical Center | Modified polypeptides with altered biological activity |
AU6046696A (en) | 1995-06-07 | 1996-12-30 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
US5677280A (en) * | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US6251864B1 (en) * | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
EP2338897A1 (en) * | 1995-06-07 | 2011-06-29 | Glaxo Group Limited | Peptides and compounds that bind to a thrombopoietin receptor |
US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5668110A (en) * | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
ES2210374T3 (es) | 1995-06-07 | 2004-07-01 | Ortho Pharmaceutical Corporation | Compuestos y peptidos que se unen al receptor de eritropoyetina. |
US5683983A (en) * | 1995-06-07 | 1997-11-04 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US6346390B1 (en) * | 1996-03-08 | 2002-02-12 | Receptron, Inc. | Receptor derived peptides involved in modulation of response to ligand binding |
US6103879A (en) * | 1996-06-21 | 2000-08-15 | Axys Pharmaceuticals, Inc. | Bivalent molecules that form an activating complex with an erythropoietin receptor |
PT964702E (pt) * | 1996-08-02 | 2006-12-29 | Ortho Mcneil Pharm Inc | Polipéptidos tendo um único polímero solúvel em água ligado ao n-terminal por covalência |
US5932546A (en) * | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
US6221608B1 (en) * | 1997-01-22 | 2001-04-24 | Ortho Pharmaceutical Corporation | Methods for identifying erythropoietin receptor binding protein |
EP1008355A1 (en) | 1998-12-08 | 2000-06-14 | Debio Recherche Pharmaceutique S.A. | Method for identifying or analyzing polymer linkage sites on macromolecules using amino acid report binding |
ATE258946T1 (de) | 1998-08-28 | 2004-02-15 | Gryphon Sciences | Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ES2388341T3 (es) | 1998-10-23 | 2012-10-11 | Kirin-Amgen Inc. | Péptidos miméticos de trombopoyetina diméricos que se unen al receptor MPL y que tienen actividad trombopoyética |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
AUPQ873300A0 (en) * | 2000-07-12 | 2000-08-03 | Medvet Science Pty. Ltd. | A binding motif of a receptor (2) |
ES2279769T3 (es) * | 1999-09-24 | 2007-09-01 | Smithkline Beecham Corporation | Mimeticos de trombopoyetina. |
EP1221482B1 (en) * | 1999-09-27 | 2005-12-28 | Chugai Seiyaku Kabushiki Kaisha | Hemopoietin receptor protein, nr12 |
US6703480B1 (en) | 1999-11-24 | 2004-03-09 | Palani Balu | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use |
US6858630B2 (en) * | 1999-12-06 | 2005-02-22 | Smithkline Beecham Corporation | Naphthimidazole derivatives and their use as thrombopoietin mimetics |
US20030125262A1 (en) * | 2000-03-21 | 2003-07-03 | Wisconsin Alumni Research Foundation | Methods and reagents for regulation of cellular responses in biological systems |
US6777387B2 (en) * | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
EP1525889A1 (en) * | 2000-05-15 | 2005-04-27 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivative |
MXPA02011727A (es) | 2000-05-26 | 2003-10-24 | Johnson & Johnson | Peptidos neuroprotectores. |
MXPA03001039A (es) * | 2000-08-02 | 2004-09-10 | Johnson & Johnson | Quimioterapia anti-viral y anti-tumor mejorada mediante administracion de eritropoeitina. |
AU2001278905B2 (en) * | 2000-09-08 | 2004-12-16 | Gryphon Therapeutics, Inc. | Synthetic erythropoiesis stimulating proteins |
CA2431964C (en) * | 2000-12-20 | 2013-09-10 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
US7767643B2 (en) * | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
AU2002251988A1 (en) | 2001-02-20 | 2002-09-04 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
FR2823220B1 (fr) * | 2001-04-04 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo) |
US20020169128A1 (en) * | 2001-04-09 | 2002-11-14 | Geroge Sigounas | Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
EA010099B1 (ru) * | 2003-05-12 | 2008-06-30 | Афимакс, Инк. | Пептиды, которые связываются с рецептором к эритропоэтину, и способы их применения |
KR101160611B1 (ko) * | 2003-05-12 | 2012-06-28 | 아피맥스, 인크. | 폴리(에틸렌 글리콜)로 변형된 펩티드 기재 화합물용 신규 스페이서 부분 |
MXPA05012316A (es) * | 2003-05-12 | 2006-04-18 | Affymax Inc | Peptidos novedosos que se unen al receptor de la eritropoyetina. |
BRPI0411160A (pt) | 2003-05-12 | 2006-07-11 | Affymax Inc | novos compostos modificados com poli(glicol etilênico) e usos dos mesmos |
-
2004
- 2004-05-12 MX MXPA05012316A patent/MXPA05012316A/es active IP Right Grant
- 2004-05-12 EP EP04760998A patent/EP1629007B1/en not_active Expired - Lifetime
- 2004-05-12 BR BRPI0411155-9A patent/BRPI0411155A/pt not_active Application Discontinuation
- 2004-05-12 SI SI200431176T patent/SI1629007T1/sl unknown
- 2004-05-12 US US10/844,968 patent/US7084245B2/en not_active Expired - Fee Related
- 2004-05-12 UA UAA200511859A patent/UA88146C2/ru unknown
- 2004-05-12 AP AP2005003470A patent/AP2042A/xx active
- 2004-05-12 DE DE602004020610T patent/DE602004020610D1/de not_active Expired - Lifetime
- 2004-05-12 ME MEP-533/08A patent/MEP53308A/xx unknown
- 2004-05-12 CN CNB2004800196261A patent/CN100441595C/zh not_active Expired - Fee Related
- 2004-05-12 JP JP2006533000A patent/JP4266028B2/ja not_active Expired - Fee Related
- 2004-05-12 CA CA2525568A patent/CA2525568C/en not_active Expired - Fee Related
- 2004-05-12 PL PL04760998T patent/PL1629007T3/pl unknown
- 2004-05-12 PT PT04760998T patent/PT1629007E/pt unknown
- 2004-05-12 DK DK04760998T patent/DK1629007T3/da active
- 2004-05-12 ES ES04760998T patent/ES2323465T3/es not_active Expired - Lifetime
- 2004-05-12 AU AU2004238870A patent/AU2004238870B8/en not_active Ceased
- 2004-05-12 NZ NZ543905A patent/NZ543905A/en not_active IP Right Cessation
- 2004-05-12 OA OA1200500316A patent/OA13164A/en unknown
- 2004-05-12 WO PCT/US2004/014889 patent/WO2004101606A2/en active Application Filing
- 2004-05-12 RS YUP-2005/0838A patent/RS51130B/sr unknown
- 2004-05-12 KR KR1020057021601A patent/KR101163683B1/ko not_active IP Right Cessation
- 2004-05-12 AT AT04760998T patent/ATE428727T1/de active
- 2004-05-12 SG SG200717599-5A patent/SG160224A1/en unknown
- 2004-05-12 EA EA200501801A patent/EA010095B1/ru not_active IP Right Cessation
-
2005
- 2005-10-27 US US11/261,157 patent/US7414105B2/en not_active Expired - Fee Related
- 2005-11-03 IL IL171782A patent/IL171782A/en not_active IP Right Cessation
- 2005-12-02 IS IS8165A patent/IS2683B/is unknown
- 2005-12-09 ZA ZA2005/10010A patent/ZA200510010B/en unknown
- 2005-12-09 NO NO20055852A patent/NO338435B1/no not_active IP Right Cessation
- 2005-12-12 CR CR8131A patent/CR8131A/es unknown
-
2006
- 2006-08-22 HK HK06109293.9A patent/HK1088616A1/xx not_active IP Right Cessation
-
2008
- 2008-07-11 US US12/171,610 patent/US7855175B2/en not_active Expired - Fee Related
- 2008-10-29 JP JP2008278252A patent/JP4768795B2/ja not_active Expired - Fee Related
-
2009
- 2009-04-28 CY CY20091100470T patent/CY1109028T1/el unknown
- 2009-04-29 HR HR20090251T patent/HRP20090251T1/xx unknown
-
2010
- 2010-11-12 US US12/945,687 patent/US8729030B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MEP53308A (en) | Novel peptides that bind to the erythropoietin receptor | |
EA200501798A1 (ru) | Новые пептиды, которые связываются с рецептором к эритропоэтину | |
WO2006062685A3 (en) | Novel peptides that bind to the erythropoietin receptor | |
UA92497C2 (ru) | Составы, которые содержат пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
CY1120670T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) | |
NO20082559L (no) | Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer | |
NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
EA200800564A1 (ru) | Производные ксантина как селективные агонисты нм74а | |
NO20054769L (no) | Substituerte fenylalkansyrer | |
EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
EA200300942A1 (ru) | Производные n-(арилсульфонил)бета-аминокислот, содержащие замещенную аминометильную группу, способ их получения и содержащие их фармацевтические композиции | |
DE602004018788D1 (de) | Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen | |
EA200601217A1 (ru) | Новые конденсированные пирролокарбазолы | |
CY1114724T1 (el) | Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων | |
MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
ATE514718T1 (de) | Peptabody für krebsbehandlung | |
EA200700990A1 (ru) | Новые пептиды, которые связывают рецептор эритропоэтина | |
EA200401289A1 (ru) | Новые противоинфекционные соединения, способы их получения и фармацевтические композиции, содержащие эти соединения | |
ATE402958T1 (de) | Antagonisten des ige-rezeptors | |
SE0300457D0 (sv) | Novel compounds | |
MY140065A (en) | Novel peptides that bind to the erythropoietin receptor | |
TW200614999A (en) | Novel peptides that bind to the erythropoietin receptor | |
EA200800392A1 (ru) | Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат |